https://twitter.com/ETNOWlive/status/1739864047468822580
This is an interview by Mr. Khorakiwala. Other than that all 13 patients who have been administered have been saved by WCK5222 the most important thing that is discussed in this interview is at 1:50 sec. Outside of international phase 3 trials they have also applied for emergency use trials to DCGI in cases where a patient has meropenem resistance. Unlike the randomised double blinded phase 3 studies my guess is this is more observational and with a much smaller set of patients. This study if successful will save a lot of lives and will also allow commercialisation of WCK5222 much quickly.
Subscribe To Our Free Newsletter |